KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$112M+67.4% YoY

Gross Profit

$63M56.0% margin

Operating Income

-$10M-8.6% margin

Net Income

-$13M-11.3% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+3.3%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$555M

Total Liabilities

$118M

Stockholders' Equity

$437M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$112M	$67M	+67.4%
Gross Profit	$63M	$40M	+58.4%
Operating Income	-$10M	-$11M	+11.6%
Net Income	-$13M	-$14M	+8.4%

Revenue Segments

Product

$112M95%

Collaboration

$6M5%

KNSA Q3 2024 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena